HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions.

AbstractBACKGROUND:
Interventional Management of Stroke III did not show that combining IV recombinant tissue plasminogen activator (rt-PA) with endovascular therapies (EVTs) is better than IV rt-PA alone.
OBJECTIVE:
To report efficacy and safety results for EVT of intracranial internal carotid artery (ICA) and middle cerebral artery trunk (M1) occlusion.
METHODS:
Five revascularization methods for persistent occlusions after IV rt-PA treatment were evaluated for prespecified primary and secondary endpoints, after accounting for differences in key baselines variables using propensity scores. Revascularization was scored using the arterial occlusive lesion (AOL) and the modified Thrombolysis in Cerebral Ischemia (mTICI) scores.
RESULTS:
EVT of 200 subjects with intracranial ICA or M1 occlusion resulted in 81.5% AOL 2-3 recanalization, in addition to 76% mTICI 2-3 and 42.5% mTICI 2b-3 reperfusion. Adverse events included symptomatic intracranial hemorrhage (SICH) (8.0%), vessel perforations (1.5%), and new emboli (14.9%). EVT techniques used were standard microcatheter n=51; EKOS n=14; Merci n=77; Penumbra n=39; Solitaire n=4; multiple n=15. Good clinical outcome was associated with both TICI 2-3 and TICI 2b-3 reperfusion. Neither modified Rankin scale (mRS) 0-2 (28.5%), nor 90-day mortality (28.5%), nor asymptomatic ICH (36.0%) differed among revascularization methods after propensity score adjustment for subjects with intracranial ICA or M1 occlusion.
CONCLUSIONS:
Good clinical outcome was associated with good reperfusion for ICA and M1 occlusion. No significant differences in efficacy or safety among revascularization methods were demonstrated after adjustment. Lack of high-quality reperfusion, adverse events, and prolonged time to treatment contributed to lower-than-expected mRS 0-2 outcomes and study futility compared with IV rt-PA.
TRIAL REGISTRATION NUMBER:
NCT00359424.
AuthorsThomas A Tomsick, Sharon D Yeatts, David S Liebeskind, Janice Carrozzella, Lydia Foster, Mayank Goyal, Ruediger von Kummer, Michael D Hill, Andrew M Demchuk, Tudor Jovin, Bernard Yan, Osama O Zaidat, Wouter Schonewille, Stefan Engelter, Renee Martin, Pooja Khatri, Judith Spilker, Yuko Y Palesch, Joseph P Broderick, IMS III Investigators
JournalJournal of neurointerventional surgery (J Neurointerv Surg) Vol. 7 Issue 11 Pg. 795-802 (Nov 2015) ISSN: 1759-8486 [Electronic] England
PMID25342652 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Chemical References
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Arterial Occlusive Diseases (drug therapy, surgery)
  • Carotid Artery, Internal (pathology)
  • Cerebral Arterial Diseases (drug therapy, surgery)
  • Cerebral Revascularization (adverse effects, methods)
  • Combined Modality Therapy
  • Endovascular Procedures (adverse effects, methods)
  • Female
  • Fibrinolytic Agents (administration & dosage, adverse effects, pharmacology)
  • Humans
  • Male
  • Middle Aged
  • Middle Cerebral Artery (pathology)
  • Outcome Assessment, Health Care
  • Tissue Plasminogen Activator (administration & dosage, adverse effects, pharmacology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: